Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.60 |
| ▸ | KLK7 | P49862 | 1/20 | 0.60 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15559104 | 1.00 | KLK5 (0.60) | KLK5KLK7PPARASYKCTSS | |
| SCHEMBL11598914 | 1.00 | KLK5 (0.60) | KLK5KLK7PPARASYKCTSS | |
| Hydrochloric Acid SCHEMBL11598965 | 0.99 | KLK5 (0.59) | KLK5KLK7PPARASYKCTSS | |
| SCHEMBL11596080 | 0.92 | REN (0.61) | KLK5KLK7CTSSCTSKREN | |
| SCHEMBL11597491 | 0.92 | KLK7 (0.54) | KLK5KLK7PPARACTSSCTSK | |
| SCHEMBL11648764 | 0.91 | KLK5 (0.52) | KLK5KLK7PPARASYKCTSS | |
| SCHEMBL11647014 | 0.91 | CTSS (0.62) | KLK5KLK7PPARACTSSCTSK | |
| SCHEMBL11599055 | 0.91 | REN (0.65) | KLK5KLK7CTSSCTSKREN | |
| SCHEMBL6178945 | 0.90 | SYK (0.55) | KLK5KLK7PPARASYKCTSS | |
| SCHEMBL7205174 | 0.90 | REN (0.61) | KLK5KLK7CTSSCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | MERCK CANADA INC. (CA) | 2012-04-26 | — | — | US | disclosed |
| EP-0445796-B1 | Derivatives of acetic acid containing peptide bonds | HOFFMANN LA ROCHE (CH) | 1998-06-17 | — | — | EP | disclosed |
| US-5162336-A | Disorders of gastrointestinal, central nervous and appetite regulatory systems | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0445796-A2 | Derivatives of acetic acid | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | CTSL, CTSS, CTSZ | KLK5 1345/4885KLK7 2533/4885PPARA 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.